Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AmiCARE: A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

NCT07469488 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT07469488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07469488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AmiCARE: A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Phase 4
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
December 31, 2029
Enrollment
122 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infusion reaction, nsclc (advanced non-small cell lung cancer), rash due to epidermal growth factor receptor inhibitors, vte (venous thromboembolism)